MX2023014275A - Métodos de tratamiento de la malignidad de células b utilizando un inhibidor de bcl-2. - Google Patents
Métodos de tratamiento de la malignidad de células b utilizando un inhibidor de bcl-2.Info
- Publication number
- MX2023014275A MX2023014275A MX2023014275A MX2023014275A MX2023014275A MX 2023014275 A MX2023014275 A MX 2023014275A MX 2023014275 A MX2023014275 A MX 2023014275A MX 2023014275 A MX2023014275 A MX 2023014275A MX 2023014275 A MX2023014275 A MX 2023014275A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- bcl
- treating
- methods
- cell malignancy
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title abstract 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000036210 malignancy Effects 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 abstract 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente divulgación proporciona métodos para tratar neoplasias malignas de células B en un sujeto con un inhibidor de Bcl-2, en particular 2-((1H-pirrolo[2,3-b]piridin-5-il)oxi)-N-((4- ((((1r,4r)-4-hidroxi-4-metilciclohexil)metil)amino) -3-nitrofenil)sulfonil)-4-(2-((S)-2-(2-isopropilfenil)pirrolidin- 1-il)-7- azaespiro[3.5]nonan-7-il)benzamida o una sal farmacéuticamente aceptable del mismo, o su combinación con un inhibidor de tirosina cinasa de Bruton (BTK), en particular (S)-7-(1-acriloilpiperidin-4-il)-2-(4- fenoxifenil)-4,5,6,7-tetrah idropirazolo-[1,5-a]pirimidin-3-carboxamida o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195892P | 2021-06-02 | 2021-06-02 | |
| US202263340642P | 2022-05-11 | 2022-05-11 | |
| PCT/US2022/031903 WO2022256489A1 (en) | 2021-06-02 | 2022-06-02 | Methods of treating b-cell malignancy using bcl-2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014275A true MX2023014275A (es) | 2024-03-06 |
Family
ID=84323554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014275A MX2023014275A (es) | 2021-06-02 | 2022-06-02 | Métodos de tratamiento de la malignidad de células b utilizando un inhibidor de bcl-2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240122932A1 (es) |
| EP (1) | EP4351542A4 (es) |
| JP (1) | JP2024522008A (es) |
| KR (1) | KR20240016335A (es) |
| AU (1) | AU2022286958A1 (es) |
| BR (1) | BR112023025123A2 (es) |
| CA (1) | CA3222029A1 (es) |
| IL (1) | IL308931A (es) |
| MX (1) | MX2023014275A (es) |
| PH (1) | PH12023553203A1 (es) |
| TW (1) | TW202313016A (es) |
| WO (1) | WO2022256489A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4051676A4 (en) | 2019-10-28 | 2023-11-22 | BeiGene, Ltd. | BCL-2 INHIBITORS |
| WO2021208963A1 (en) | 2020-04-15 | 2021-10-21 | Beigene, Ltd. | Bcl-2 inhibitor |
| TW202400163A (zh) * | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法 |
| CN119301117A (zh) * | 2022-12-27 | 2025-01-10 | 百济神州(苏州)生物科技有限公司 | Sonrotoclax中间体的盐及固体形式 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014339816B2 (en) * | 2013-10-25 | 2020-05-28 | Pharmacyclics Llc | Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy |
| PL3179991T3 (pl) * | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| EP3788042B1 (en) * | 2018-04-29 | 2025-02-12 | BeiGene Switzerland GmbH | Bcl-2 inhibitors |
| CN110776507B (zh) * | 2018-07-31 | 2020-12-18 | 苏州亚盛药业有限公司 | Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途 |
| CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2022
- 2022-06-02 JP JP2023574114A patent/JP2024522008A/ja active Pending
- 2022-06-02 CA CA3222029A patent/CA3222029A1/en active Pending
- 2022-06-02 AU AU2022286958A patent/AU2022286958A1/en active Pending
- 2022-06-02 PH PH1/2023/553203A patent/PH12023553203A1/en unknown
- 2022-06-02 BR BR112023025123A patent/BR112023025123A2/pt unknown
- 2022-06-02 WO PCT/US2022/031903 patent/WO2022256489A1/en not_active Ceased
- 2022-06-02 IL IL308931A patent/IL308931A/en unknown
- 2022-06-02 MX MX2023014275A patent/MX2023014275A/es unknown
- 2022-06-02 EP EP22816826.6A patent/EP4351542A4/en active Pending
- 2022-06-02 KR KR1020237045066A patent/KR20240016335A/ko active Pending
- 2022-06-02 TW TW111120658A patent/TW202313016A/zh unknown
-
2023
- 2023-11-30 US US18/524,170 patent/US20240122932A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240122932A1 (en) | 2024-04-18 |
| TW202313016A (zh) | 2023-04-01 |
| JP2024522008A (ja) | 2024-06-06 |
| KR20240016335A (ko) | 2024-02-06 |
| AU2022286958A1 (en) | 2023-12-21 |
| BR112023025123A2 (pt) | 2024-02-20 |
| IL308931A (en) | 2024-01-01 |
| WO2022256489A1 (en) | 2022-12-08 |
| CA3222029A1 (en) | 2022-12-08 |
| PH12023553203A1 (en) | 2024-02-19 |
| EP4351542A1 (en) | 2024-04-17 |
| EP4351542A4 (en) | 2025-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014275A (es) | Métodos de tratamiento de la malignidad de células b utilizando un inhibidor de bcl-2. | |
| MX386416B (es) | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. | |
| RU2306313C2 (ru) | Производные имидазо(или триазоло)пиримидина, способ их получения и лекарственное средство, ингибирующее активность тирозинкиназы syk | |
| CO2017005483A2 (es) | Forma cristalina de sulfato de hidrógeno de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1- il)-pirazol[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida | |
| CL2008001862A1 (es) | Forma cristalina i, iii e hidratada de 6-{difluoro-[6-(1-metil-1h-pirazol-4-il)[1,2,4]triazolo[4,3-b]piridazin-3-il]metil}quinolina; composicion farmaceutica que las comprende; y su uso para prevenir o tratar un un trastorno proliferativo celular. | |
| CL2008002687A1 (es) | Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico. | |
| ZA201806684B (en) | Methods of treating pediatric cancers | |
| PL3800189T3 (pl) | Wytwarzanie (s)-n-(5-((r)-2-(2,5-difluorofenylo)pirolidyn-1-ylo)pirazolo[1,5-a]pirymidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu | |
| RU2002132193A (ru) | Производные имидазопиримидина и производные триазолопиримидина | |
| NZ598086A (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
| MX2022004729A (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y segundos principios activos para uso combinado. | |
| WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
| CY1113670T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| CR10450A (es) | Metodo para inhibir la cinasa del c-kit | |
| MX2024013875A (es) | Metodos de tratamiento de las neuropatias mieloides utilizando un inhibidor de bcl-2 | |
| PH12020551583A1 (en) | Anticancer pharmaceutical compositions for combined therapy | |
| CA2677690A1 (en) | Treatment of comorbid premature ejaculation and erectile dysfunction | |
| AR045875A1 (es) | Procedimiento para la preparacion del antagonista ccr-2 | |
| MX2025000776A (es) | Metodos de tratamiento del mieloma multiple con un inhibidor de bcl-2 | |
| MX2024002465A (es) | Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos. | |
| RU2023134262A (ru) | Способы лечения b-клеточного злокачественного образования с использованием ингибитора bcl-2 | |
| JOP20180088A1 (ar) | صيغ سائلة من (s)-n-(5-((r)-2-(2، 5-داي فلورو فينيل)-بيروليدين-1-يل)-بيرازولو[1، 5-a] بيريميدين-3-يل)-3-هيدروكسي بيروليدين-1-كربوكساميد | |
| MX2025004895A (es) | Metodos para el tratamiento de la nefropatia membranosa primaria |